PERSPECTIVE THERAPEUTICS
Live / Applied — Non-final action mailed (as of 10 Sept 2026)
What this means for you
Not registered yet, but its 23 Jun 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99900238
- Mark type
- Design + words
- Filed
- 23 Jun 2026
- Attorney of record
- Sandra L Etherton
Goods and services
- Class 001 — Chemicals: Active chemical ingredients for use in the manufacture of anti-cancer drugs; radiopharmaceutical chemical compounds; radiolabeled chemical compounds comprising alpha-emitting radionuclides; bifunctional chelating agents for conjugating radionuclides to targeting molecules; chemical precursors for use in the manufacture of radiopharmaceuticals; chelating compounds for radiolabeling of peptides and small molecules; radioactive isotope-labeled chemical intermediates for pharmaceutical research and manufacturing
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of cancer; radiopharmaceutical preparations for the treatment of cancer; radiopharmaceutical preparations for the diagnosis of cancer; targeted alpha therapy radiopharmaceutical preparations for the treatment of cancer comprising prostate cancer, breast cancer, pancreatic cancer, colorectal cancer, or neuroendocrine tumors; radioligand therapy preparations comprising radiolabeled targeting compounds for oncological use; radiopharmaceutical diagnostic agents for use in nuclear medicine imaging; radiopharmaceutical preparations for the treatment of cancers; radiolabeled peptide conjugates for use in cancer therapy; radiopharmaceutical preparations for theranostic applications in oncology
- Class 042 — Scientific and technological services: Medical and scientific research in the field of cancer treatment and diagnosis; scientific research and development services in the field of radiopharmaceuticals and nuclear medicine; contract research services in the field of radiopharmaceutical drug discovery and development; preclinical research and development services relating to radiolabeled compounds for cancer therapy and diagnosis; scientific consultation services in the field of targeted radionuclide therapy; laboratory research services in the field of radiochemistry and radiopharmaceutical development; drug discovery research services in the field of oncology radiopharmaceuticals; scientific and technological services relating to the development of targeted alpha therapy compounds; research and development services relating to theranostic radiopharmaceutical platforms
Owner
- Perspective Therapeutics, Inc., Seattle, WA, US
Prior registrations
Prosecution history
- 10 Sept 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Sept 2026 — NON-FINAL ACTION E-MAILED
- 10 Sept 2026 — NON-FINAL ACTION WRITTEN
- 10 Sept 2026 — ASSIGNED TO EXAMINER
- 10 Sept 2026 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 10 Sept 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 23 Jun 2026 — APPLICATION FILING RECEIPT MAILED
- 23 Jun 2026 — NEW APPLICATION ENTERED